1. Home
  2. CCIF vs KYTX Comparison

CCIF vs KYTX Comparison

Compare CCIF & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CCIF
  • KYTX
  • Stock Information
  • Founded
  • CCIF 2011
  • KYTX 2018
  • Country
  • CCIF United States
  • KYTX United States
  • Employees
  • CCIF N/A
  • KYTX N/A
  • Industry
  • CCIF Finance/Investors Services
  • KYTX
  • Sector
  • CCIF Finance
  • KYTX
  • Exchange
  • CCIF Nasdaq
  • KYTX NYSE
  • Market Cap
  • CCIF 130.8M
  • KYTX 125.2M
  • IPO Year
  • CCIF N/A
  • KYTX 2024
  • Fundamental
  • Price
  • CCIF $6.73
  • KYTX $1.86
  • Analyst Decision
  • CCIF
  • KYTX Buy
  • Analyst Count
  • CCIF 0
  • KYTX 5
  • Target Price
  • CCIF N/A
  • KYTX $18.80
  • AVG Volume (30 Days)
  • CCIF 76.9K
  • KYTX 298.8K
  • Earning Date
  • CCIF 01-01-0001
  • KYTX 05-13-2025
  • Dividend Yield
  • CCIF 25.90%
  • KYTX N/A
  • EPS Growth
  • CCIF N/A
  • KYTX N/A
  • EPS
  • CCIF N/A
  • KYTX N/A
  • Revenue
  • CCIF N/A
  • KYTX N/A
  • Revenue This Year
  • CCIF N/A
  • KYTX N/A
  • Revenue Next Year
  • CCIF N/A
  • KYTX N/A
  • P/E Ratio
  • CCIF N/A
  • KYTX N/A
  • Revenue Growth
  • CCIF N/A
  • KYTX N/A
  • 52 Week Low
  • CCIF $7.43
  • KYTX $1.79
  • 52 Week High
  • CCIF $10.16
  • KYTX $22.44
  • Technical
  • Relative Strength Index (RSI)
  • CCIF 39.74
  • KYTX 39.01
  • Support Level
  • CCIF $6.27
  • KYTX $1.81
  • Resistance Level
  • CCIF $7.10
  • KYTX $2.27
  • Average True Range (ATR)
  • CCIF 0.36
  • KYTX 0.21
  • MACD
  • CCIF 0.03
  • KYTX 0.02
  • Stochastic Oscillator
  • CCIF 66.10
  • KYTX 16.33

About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest

Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.

About KYTX KYVERNA THERAPEUTICS INC

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Share on Social Networks: